BioSpace News Archive

Owens & Minor, Inc. reported financial results for the second quarter of 2020, as summarized in the table below.

Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced today the appointment of Barclay “Buck” Phillips as chief operating officer and chief financial officer

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its full financial and operational results for the quarter ending June 30, 2020.

Healthpeak Properties, Inc. (NYSE: PEAK) today announced results for the second quarter ended June 30, 2020.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2020.

New mid-scale microbial facility to support Servier with active pharmaceutical ingredient (API) for acute lymphoblastic leukemia (ALL) therapies

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced financial results for the second quarter ended June 30, 2020 (“Q2 2020”).

Expansion of Fourth Round of Capital to be used to Complete Development of Compact, Innovative, Needle-Free Device for Administration of Emergency Epinephrine [04-August-2020] RALEIGH, N.C. , Aug. 4, 2020 /PRNewswire/ -- Bryn Pharma, LLC (“Bryn” or the “Company”), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers t

BostonGene Corporation (BostonGene), a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced its collaboration with The Weinstock Laboratory, a translational research program focused on novel therapeutics for lymphoid malignancies, at Dana-